Your browser doesn't support javascript.
loading
Bortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: a multicenter phase II clinical trial.
Isoda, Atsushi; Murayama, Kayoko; Ito, Shigeki; Kohara, Yoichi; Iino, Masaki; Miyazawa, Yuri; Matsumoto, Morio; Handa, Hiroshi; Imai, Yosuke; Ishiguro, Takuro; Izumita, Wataru; Kitano, Kiyoshi; Hirabayashi, Yukio; Nakazawa, Hideyuki; Ishida, Fumihiro; Mitsumori, Toru; Kirito, Keita; Chou, Takaaki; Murakami, Hirokazu.
Affiliation
  • Isoda A; Department of Hematology, National Hospital Organization Shibukawa Medical Center, 383 Shiroi, Shibukawa, Gunma, 377-0280, Japan. aisoda@sbmc.hosp.go.jp.
  • Murayama K; Department of Hematology, Gunma Cancer Center, Gunma, Japan.
  • Ito S; Department of Medical Oncology, Iwate Medical University School of Medicine, Iwate, Japan.
  • Kohara Y; Department of Hematology, Showa Inan General Hospital, Nagano, Japan.
  • Iino M; Department of Medical Oncology, Yamanashi Prefectural Central Hospital, Yamanashi, Japan.
  • Miyazawa Y; Department of Hematology, National Hospital Organization Shibukawa Medical Center, 383 Shiroi, Shibukawa, Gunma, 377-0280, Japan.
  • Matsumoto M; Department of Hematology, National Hospital Organization Shibukawa Medical Center, 383 Shiroi, Shibukawa, Gunma, 377-0280, Japan.
  • Handa H; Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Gunma, Japan.
  • Imai Y; Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
  • Ishiguro T; Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
  • Izumita W; Department of Hematology, Iwate Prefecture Ofunato Hospital, Iwate, Japan.
  • Kitano K; Department of Hematology, National Hospital Organization Matsumoto Medical Center, Nagano, Japan.
  • Hirabayashi Y; Department of Hematology, National Hospital Organization Matsumoto Medical Center, Nagano, Japan.
  • Nakazawa H; Division of Hematology, Department of Internal Medicine, Shinshu University School of Medicine, Nagano, Japan.
  • Ishida F; Department of Biomedical Laboratory Medicine, Shinshu University School of Medicine, Nagano, Japan.
  • Mitsumori T; Division of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan.
  • Kirito K; Division of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan.
  • Chou T; Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
  • Murakami H; Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Gunma, Japan.
Int J Hematol ; 108(1): 39-46, 2018 Jul.
Article in En | MEDLINE | ID: mdl-29594921
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Induction Chemotherapy / Maintenance Chemotherapy / Bortezomib / Multiple Myeloma / Antineoplastic Agents Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Int J Hematol Journal subject: HEMATOLOGIA Year: 2018 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Induction Chemotherapy / Maintenance Chemotherapy / Bortezomib / Multiple Myeloma / Antineoplastic Agents Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Int J Hematol Journal subject: HEMATOLOGIA Year: 2018 Document type: Article Affiliation country: Country of publication: